Acasti receives extension to regain compliance with nasdaq minimum bid price rule

Laval, quÉbec, jan. 25, 2023 (globe newswire) -- acasti pharma inc. (“acasti” or the “company”) (nasdaq: acst and tsx-v: acst), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that it has received notification from the nasdaq listing qualifications department ("nasdaq") that it is eligible for an additional 180 calendar days, or until july 24, 2023, to regain compliance with the minimum $1.00 per share requirement for continued listing.
ACST Ratings Summary
ACST Quant Ranking